Sensei Biotherapeutics, Inc. · NASDAQ:SNSE
Sensei Biotherapeutics — Faeth Therapeutics — Investor Presentation (October 2026)
39 slides from Sensei Biotherapeutics's investor presentation, October 2026
Slide 1: Break through the PAM barrier.
FAETH THERAPEUTICS COMPANY OVERVIEW Break through the PAM barrier. Oral inhibition of the PI3K/AKT/mTOR pathway, one of the most frequently altered pathways in cancer. OCTOBER 2026 © 2026 Faeth Therapeutics. 1
Slide 2: Forward-Looking Statements
— Forward-Looking Statements Certain matters discussed in this Presentation may contain forward-looking statements made by Faeth Therapeutics, Inc. (the “Company”) that are, by their nature, subject to significant risks and uncertainties. Forward-looking statements can be identified by words such as
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS COMPLETE PAM Oral multi-node blockade that hits PAM at the three nodes Oral PAM1 regimen, built for BLOCKADE that we believe matter. longer target coverage without class-defining toxicities PK EDGE Intermittent dosing schedule that has been observed to flatten (TOLERABILITY AND
Slide 4: Built on work by Dr. Lewis Cantley; scientific co-founders
INTRODUCTION — Built on work by Dr. Lewis Cantley, discoverer of the PI3K pathway. Molecules designed by Kevan Shokat, one of the world’s leading medicinal chemists FAETH SCIENTIFIC CO-FOUNDERS Lew Cantley, PhD Sid Mukherjee, MD PhD Dana Farber Cancer Institute, Harvard. Founder: Agios (NASDAQ), Ass
Slide 5: PIKTOR: Designed for potent and selective multi-node PI3K/AKT/mTOR pathway inhibition
PIKTOR OVERVIEW — PIKTOR: Designed for potent and selective multi-node PI3K/AKT/mTOR pathway inhibition PIKTOR combines serabelisib (PI3K-alpha specific inhibitor) with sapanisertib (mTORC1 and mTORC2 inhibitor). serabelisib PI3K-alpha PIKTOR specific inhibitor Targeting the PI3K/AKT/mTOR pathway to
Slide 6: Multi-node synergy allows lower doses than monotherapy RP2D
PIKTOR OVERVIEW — Multi-node synergy designed to allow each agent to run using multiple-fold lower doses than monotherapy RP2D MONOTHERAPY RP2D DOSE IN PIKTOR + PACLITAXEL³ REDUCTION Serabelisb 900 mg QD×3dQW ¹ 200 mg QD×3dQW 4.5× lower PIKTOR Sapanisertib 9 mg QD×3dQW ² 3 mg QD×3dQW 3× lower Why th
Slide 7: Multi-node inhibition achieved robust preclinical PI3K-pathway inhibition in cancer cell lines
PIKTOR OVERVIEW — Multi-node inhibition with PIKTOR achieved robust preclinical PI3K-pathway inhibition in cancer cell lines PIKTOR reduced PI3K-pathway signaling in cancer cell lines more than single-node inhibitors at clinically relevant concentrations¹ Preclinical data have been recapitulated in
Slide 8: Oral PIKTOR dosing designed for sustained exposure with reduced Cmax-related toxicity risk
PIKTOR OVERVIEW — Oral PIKTOR dosing is designed for sustained exposure with reduced Cmax-related toxicity risk Plasma protein Peak Time above binding / free exposure IC90 / fraction (Cmax : IC90 week ratio) Bound Free Serabelisib 2.2 42 h 69% 31% Multiple of IC90 (log scale) Sapanisertib 2.9 44 h 7
Slide 9: PIKTOR had low rates of stomatitis and hyperglycemia vs. other PAM agents
PIKTOR OVERVIEW — PIKTOR had low rates of both stomatitis and hyperglycemia in ongoing Phase 2 endo trial vs. other PAM agents Point labels: stomatitis% / hyperglycemia% 100 PIKTOR Comparators Hyperglycemia, any grade (% of PIK-201 (n=22): patients are not 75 Inavolisib required to use steroid 90% /
Slide 10: PIKTOR: Designed to solve the challenges of drugging the PI3K pathway
PIKTOR OVERVIEW — PIKTOR: Designed to solve the challenges of drugging the PI3K pathway MULTI-NODE SINGLE-NODE PIKTOR GEDATOLISIB MUTANT-SPECIFIC FDA-APPROVED Celcuity (Approved)) Relay, Lilly, OnKure, Novartis Alpelisib, Everolimus, (Ph.2, Endometrial, Ph.1b Breast) (Investigational) Capivasertib,
Slide 11: 2L+ endometrial market, rising unmet need, one PAM-pathway option
CLINICAL DEVELOPMENT: ENDOMETRIAL — 2L+ endometrial market, rising unmet need, one PAM- pathway option Expanding market Endometrial cancer is a growing market and ADC PAM recently overtook ovarian as the deadliest 6+ sponsors5 · Ph2/3 1 program · oral gynecological cancer1. High unmet need Paclitaxe
Slide 12: Estimated PIKTOR addressable U.S. population (2L+) ~$1.5B
MARKET: ENDOMETRIAL — Estimated PIKTOR addressable U.S. population (2L+) U.S. Incident Therapeutic Build (Annual) Anticipated FDA Label Population U.S. New Uterine Cancer Cases1 ~68,000 Post-1L advanced/recurrent endometrioid EC • Endometrioid histology Endometrioid Histology (~80%)2 ~54,000 • Advan
Slide 13: Ph1b: PIKTOR + paclitaxel drove deep responses in endometrial cancer
CLINICAL DEVELOPMENT: ENDOMETRIAL — Ph1b: PIKTOR + paclitaxel drove deep responses in endometrial cancer ALL PATIENTS (RESPONSE EVALUABLE) 47% overall response rate 73% clinical benefit rate ENDOMETRIAL PATIENTS ONLY 80% overall response rate (4/5) 3 complete responses 11 mo median PFS Range 0–26.9
Slide 14: PIK-201: PIKTOR + paclitaxel in advanced endometrial cancer
CLINICAL DEVELOPMENT: ENDOMETRIAL — PIK-201: PIKTOR + paclitaxel in advanced endometrial cancer (currently enrolling) Eligibility Criteria Phase 2 Primary endpoint Single arm (n≅40) • ORR • Endometrioid endometrial cancer • Sapanisertib 3 mg Secondary endpoints • 2nd line or later • Serabelisib 200
Slide 15: Regulatory positioning supports accelerated path to registrational trial
REGULATORY — We believe regulatory positioning supports accelerated path to registrational trial Combination Dosing Precedent Precedent supports a PI3K/mTOR multi-node strategy • Recent gedatolisib Ph3 success reinforces the class and mechanism1 Clin Pharm Gaps and Requirements Defined Strong safety
Slide 16: Breast Cancer: Multi-node PAM blockade more than doubles addressable market
CLINICAL DEVELOPMENT: BREAST — Breast Cancer: Multi-node PAM blockade more than doubles addressable market relative to mutant-selective inhibitors High unmet need HR+/HER2- patients comprise ~70% of all PI3K MUT PI3K WT + PI3K MUT metastatic breast cancer patients1 ~40% of HR+/HER2- breast cancer wi
Slide 17: HR+/HER2- breast cancer: Large unmet need
MARKET: BREAST — HR+/HER2- breast cancer: Large unmet need Three addressable patient populations from the ~48k advanced pool U.S. Incident Therapeutic Build (Annual) U.S. New Breast Cancer Cases1 ~48,000 ~$10B ~316,000 1L patients receiving U.S. TAM4 aromatase inhibitor + CDK4/6 HR+/HER2− Subtype (~
Slide 18: Serabelisib and Sapanisertib each shown activity in HR+/HER2- breast cancer
CLINICAL DEVELOPMENT: BREAST — Serabelisib and Sapanisertib have each independently shown activity in HR+/HER2- breast cancer; Phase 1b/2 underway STUDY DRUG / COMBINATION ORR DCR mPFS CR Garcia-Saenz et. al., Sapanisertib + Fulvestrant 21.3% 75% PR+CR+SD 7.2 m 2/47 Sapanisertib 2022 1 (n=47 arm B)
Slide 19: Breast: First patient dosed in Phase 1b trial in April 2026
KEY MILESTONES — Breast: First patient dosed in Phase 1b trial in April 2026 Achieved in 2026 227 2027 2028 Trial initiated; Ph1b Interim safety data dose escalation Expansion data from dose escalation underway Interim efficacy data; First patient dosed expansion cohorts Apr 2026 initiated © 2026 Fa
Slide 20: Breast: Ongoing Phase 1b/2 trial design
CLINICAL DEVELOPMENT: BREAST — Breast: Ongoing Phase 1b/2 trial designed to rapidly identify recommended dose and initiate expansion cohorts Cohort A Cohort B Planned Cohort C PIKTOR + Fulvestrant PIKTOR + Fulvestrant + PIKTOR + Oral SERD ± Palbociclib Palbociclib B4 (optional): Sap 4 mg + Ser 300 m
Slide 21: Two clinically de-risked indications add optionality to pipeline
PIPELINE OPTIONALITY — Two clinically de-risked indications outside of endometrial cancer and breast cancer add optionality to pipeline Ovarian Lung Platinum-resistant ovarian cancer (PROC) NFE2L2/KEAP1-mutated advanced NSCLC HR 0.66 25% ORR PFS benefit in randomized Phase 2 DICE trial (90% CI: 0.45
Slide 22: $186.4M cash expected to fund PIKTOR through anticipated readouts
KEY MILESTONES — $186.4M1 in cash expected to fund PIKTOR through anticipated readouts in endometrial cancer and breast cancer PROGRAM Achieved in 2026 2H 2026 2272027 2028+ Received Fast Track Last patient dosed + 6 ENDOMETRIAL Topline data readout Designation months data Trial initiated; Ph1b - In
Slide 23: Robust IP portfolio and registration-ready CMC
IP & CMC — Robust IP portfolio and registration-ready CMC Intellectual property CMC & supply May 2037 — Composition of matter Mature DS/DP materials Issued COM patents for both APIs; serabelisib ISSUED Both drug substances highly stable; batches with 36–60 expiry includes PTA and expected 5 years of
Slide 24: Faeth team has deep drug development experience
TEAM — Faeth team has deep drug development experience Management team Board Oliver Maddocks, Anand Parikh, JD Anand Parikh, JD Phil Donenberg Chief Executive Officer MPharm PhD Board Chair Board Member Chief Scientific Officer Brian Stephenson, Debbie Chirnomas, Stephen Hahn, MD Saira Ramasastry Ph
Slide 25: Appendix
Appendix © 2026 Faeth Therapeutics. 25
Slide 26: PIKTOR demonstrated preclinical pathway suppression at lower concentrations
PIKTOR OVERVIEW — PIKTOR demonstrated preclinical pathway suppression at lower concentrations than other PI3K/AKT/mTOR targeted agents Cell Line PI3K-Pathway Status Serabelisib 1 Sapanisertib 1 PIKTOR 1 Gedatolisib 2 Alpelisib 1 Everolimus 1 Capivasertib 1 RLY-2608 1 STX-478 1 Inavolisib 1 Paclitaxe
Slide 27: Ph1b: PIKTOR + paclitaxel showed durable responses in PIK3CAmut and wt patients
CLINICAL DEVELOPMENT: ENDOMETRIAL — Ph1b: PIKTOR + paclitaxel showed durable responses in both PIK3CAmut and wt patients PIKTOR AND PACLITAXEL (all RECIST evaluable) 47% Overall Response Rate ORR in patients with PI3k pathway 71% mutation Clinical Benefit Rate in evaluated 73% patients Endometrial p
Slide 28: Taxane resistance activates PI3K/AKT/mTOR signaling, sensitive to PIKTOR
CLINICAL DEVELOPMENT: ENDOMETRIAL — Taxane resistance activates PI3K/AKT/mTOR pathway signaling in cancer models, sensitive to inhibition by PIKTOR Taxane resistance activates Taxane resistant cells retain sensitivity to PIKTOR PAM Pathway © 2026 Faeth Therapeutics. Tyrakis et. al., (2025) British J
Slide 29: Phase 1 Clinical Data Comparisons (all monotherapy)
MONOTHERAPY ACTIVITY ANALYSIS — Phase 1 Clinical Data Comparisons (all monotherapy) REFERENCE COHORT ORR DCR (PR+CR+SD) All Comers (n= 71) 5.2% 40.3% Serabelisb Juric et. al., 2017 Breast Cancer (n=21) 14% 76% PIKTOR Sapanisertib Voss et. al., 2020 All Comers (n= 198) 5.0% 42.4% Breast Cancer (n=16)
Slide 30: Ovarian cancer: estimated PIKTOR addressable U.S. population
CLINICAL DEVELOPMENT: OVARIAN — Ovarian cancer: estimated PIKTOR addressable U.S. population U.S. Incident Therapeutic Build (Annual) Anticipated FDA Label Population U.S. New Ovarian Cancer Cases ~21,000 Advanced platinum resistant ovarian cancer (PROC) • Epithelial ovarian, fallopian tube, and per
Slide 31: Phase 2 DICE Trial: Sapanisertib + Paclitaxel in PROC
CLINICAL DEVELOPMENT: OVARIAN — Phase 2 DICE Trial: Sapanisertib + Paclitaxel in PROC Platinum Resistant Ovarian Cancer Eligibility Criteria Arm A: Endpoints Control (n=66) • Epithelial ovarian / • Primary endpoint: PFS fallopian tube / peritoneal Paclitaxel 80 mg/m² IV • Secondary endpoints: • Plat
Slide 32: Phase 2 DICE Trial demonstrated benefits in PROC
CLINICAL DEVELOPMENT: OVARIAN — Phase 2 DICE Trial: Sapanisertib + Paclitaxel demonstrated benefits in PROC Late breaking oral pres at ESMO Mean PFS Grade 3/4 AEs Next steps Arm A: 4.0 months Arm A: 6.6% • OS, ORR and detailed safety data to come Arm B: 5.8 months Arm B: 7.0% • Potential FDA interac
Slide 33: Phase 2 DICE Trial PFS
CLINICAL DEVELOPMENT: OVARIAN Phase 2 DICE Trial PFS Sapanisertib (aka TAK 228) and Paclitaxel showed PFS benefit in PROC Krell, J. et. al., ESMO 2025 © 2026 Faeth Therapeutics. Abbreviations: PFS - progression free survival, CI - Confidence Interval 33
Slide 34: Lung cancer: estimated PIKTOR addressable U.S. population
CLINICAL DEVELOPMENT: LUNG — Lung cancer: estimated PIKTOR addressable U.S. population U.S. Incident Therapeutic Build (Annual) Anticipated FDA Label Population U.S. New Lung Cancer Cases ~227,000 Advanced or metastatic non-small cell lung cancer (NSCLC) • Progressed on prior systemic therapy (plati
Slide 35: Sapanisertib shows preclinical efficacy in lung cancer models
CLINICAL DEVELOPMENT: LUNG Sapanisertib shows preclinical efficacy in lung cancer models LK-2 Squamous cell lung cancer xenograft tumor model (NFE2L2 E79K mutant) Vehicle Control Tumor Volume (mm3) Sapanisertib showed benefit versus Everolimus everolimus Sapanisertib 3 mg/kg PO QD Everolimus 3 mg/kg
Slide 36: Phase 2 NSCLC Trial: Sapanisertib demonstrated benefits
CLINICAL DEVELOPMENT: LUNG — Phase 2 NSCLC Trial: Sapanisertib demonstrated benefits Key results PIKTOR implications Sapanisertib monotherapy: 25% ORR and mPFS of 8.9 Established single-agent proof of concept for mTORC1/2 months in patients with NFE2L2-altered squamous NSCLC inhibition in this bioma
Slide 37: Key patents
IP — Key patents SUBJECT MATTER PATENT EXPIRATION DATE NOTES • Issued COM patents for each API Composition of Matter • COM expiry date includes patent term adjustment (PTA) • Serabelisib API May 2037 and expected 5 years of patent term extension (PTE) • Sapanisertib API added to serabelisib COM pate
Slide 38: Focused pipeline of potentially best-in-class product candidates
INTRODUCTION — Focused pipeline of potentially best-in-class product candidates, leveraging Faeth’s unique metabolic insights PIPELINE AND PROGRAM TARGET POPULATION PRECLINICAL PHASE I PHASE II PHASE III Oncology: PIKTOR PIK-201 Endometrial Oncology: PIKTOR PIK-101 Breast Oncology: Ovarian SAPANISER
Slide 39: Thank you
Thank you © 2026 Faeth Therapeutics. 39
Faeth Therapeutics — Investor Presentation (October 2026) on 6ix